Continuous Glucose Sensing at the Site of Subcutaneous Insulin Administration

Medical University of Graz10 enrolled

Overview

The study seeks to evaluate a novel treatment approach for performing continuous real-time glucose sensing and insulin delivery at the same subcutaneous tissue site.

The treatment of type 1 diabetes usually comprises the measurement of glucose in blood obtained by finger pricking and the administration of insulin via subcutaneous bolus injection or continuous subcutaneous infusion. This study seeks to test a new treatment approach where glucose sensing and insulin administration are combined and performed at a single subcutaneous tissue site (single-port treatment approach). A single-port device consisting of a continuous glucose sensor and an insulin infusion cannula is inserted into the subcutaneous tissue of 10 type-1 diabetes patients and used for insulin infusion and simultaneous glucose sensing over a 7-day period. The performance of the single-port device is assessed by comparing the obtained glucose readings with those of a blood glucose meter and an additionally worn control sensor.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Type 1 Diabetes

Interventions

insulin deliveryDRUG

Subcutaneous insulin (100 U/ml, NovoRapid®; Novo Nordisk, Bagsvaerd, Denmark) delivery with an insulin pump (Vibe-TM; Animas Corp., West Chester, PA, USA) and an insulin infusion cannula (SOF-SET MICRO QR 6mm; Medtronic MiniMed, USA) placed at the same site as the continuous glucose sensor.

glucose sensingDEVICE

Glucose sensing with a continuous glucose sensor (Dexcom G4 Platinum Sensor; Dexcom Inc., San Diego, USA) placed at the site of subcutaneous insulin delivery.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 to 65 years of age, both inclusive * Type 1 diabetes treated with Continuous Subcutaneous Insulin Infusion (CSII) * HbA1C \< 10% * Signed informed consent before any study-related activities Exclusion Criteria: * Severe acute diseases * Clinically overt diabetic complications * Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation * Taking of any vasoactive substances or anticoagulation medication * Diseases of the skin which could interfere with application of the catheters and Sensors as judged by the investigator * Pregnancy, breastfeeding, intention of becoming pregnant or not using adequate contraception. * Increased tendency towards development of hypoglycaemia * Any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the subject * Concurrent participation in another study

Locations (1)

Medical University of Graz

Graz, Styria, Austria

Outcomes

Primary Outcomes

Mean absolute relative difference between sensor readings and capillary glucose readings

Mean absolute relative differences calculated by determining the mean of the absolute value of the percentage difference between paired sensor and capillary glucose concentration

Time frame: 7 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.